BackStrongbridge Biopharma plc Overview

Strongbridge Biopharma plc Other Current Liabilities

Strongbridge Biopharma plc's other current liabilities is $22M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$21.59M
24.37% YoYΔ $4.23M vs prior year quarter

Peer average

Loading

Strongbridge Biopharma plc Other Current Liabilities History

Loading

Strongbridge Biopharma plc vs. peers: Other Current Liabilities Comparison

Loading

Strongbridge Biopharma plc Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Strongbridge Biopharma plc (SBBP) FAQ

Strongbridge Biopharma plc (SBBP) currently reports a other current liabilities of $22M as of June 2021. That compares with $17M in the prior-year period — up 24.4% year over year. Use the charts on this page to explore Strongbridge Biopharma plc's other current liabilities history and peer comparisons.

Strongbridge Biopharma plc's other current liabilities increased from $17M to $22M — a 24.4% year-over-year increase (period ending June 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Strongbridge Biopharma plc reported $22M in other current liabilities as of June 2021. That compares with $17M in the prior-year period — up 24.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $22M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Strongbridge Biopharma plc, and consider following SBBP for alerts when major investors trade the stock.

Strongbridge Biopharma plc is classified in the Healthcare sector. On other current liabilities, it currently shows $22M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SBBP with unrelated industries.